NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

NeoGenomics Inc.

In a report released today, Ian Gillies from Stifel Nicolaus maintained a Buy rating on Neo Performance Materials Inc, with a price target of C$22....

Stifel Nicolaus Sticks to Its Buy Rating for Neo Performance Materials Inc (NEO)

Neo Performance Materials Inc ( ($TSE:NEO) ) has issued an announcement. Neo Performance Materials Inc. reported strong third-quarter financial res...

Neo Performance Materials Reports Strong Q3 2025 Results and Expands European Operations

Companies in the Industrial Goods sector have received a lot of coverage today as analysts weigh in on NeoVolta (NEOV – Research Report) and Elemen...

Analysts Conflicted on These Industrial Goods Names: NeoVolta (NEOV) and Element Fleet Management (OtherELEEF)

San Diego, USA, November 11th, 2025, FinanceWire Revenue of $6.7 Million Reflects 1,027% Year-Over-Year Growth; Fourth Consecutive Record-Setting Q...

NeoVolta Reports Record First Quarter Fiscal 2026 Results

Neonode ( ($NEON) ) has released its Q3 earnings. Here is a breakdown of the information Neonode presented to its investors. Neonode Inc., based in...

Neonode Reports Strong Income Despite Revenue Decline

William Blair analyst Andrew Brackmann maintained a Hold rating on NeoGenomics today. The company’s shares closed yesterday at $10.16. According to...

William Blair Sticks to Their Hold Rating for NeoGenomics (NEO)

The latest announcement is out from Neogen ( ($NEOG) ). On October 23, 2025, Neogen held its 2025 Annual Meeting of Shareholders, where 195,086,461...

Neogen Shareholders Elect Directors, Reject Executive Pay

Neola Medical AB (($SE:NEOLA)) announced an update on their ongoing clinical study. Study Overview: Neola Medical AB is conducting a pivotal study ...

Neola Medical’s Pivotal Study: A Game Changer in Neonatal Lung Monitoring?

Craig-Hallum analyst William Bonello maintained a Buy rating on NeoGenomics today. The company’s shares opened today at $10.75. According to TipRan...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NEO	$11.48	+8.30%	2.61M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NEO	$11.48	+8.3%	2.61M
3
4
5
6

NEO

NEO

No Data Available

Get NeoGenomics Inc. Data in Excel

Get NeoGenomics Inc. Data in Excel